IP Library › Granted Patent US 12,194,093
Granted Patent B2
US 12,194,093 · App. 18/143,978 · Granted Jan 14, 2025

Dosing parameters for CD47 targeting therapies to hematologic malignancies

Inventors: Ravindra Majeti (Palo Alto, CA); Mark Ping Chao (Palo Alto, CA); Jie Liu (Palo Alto, CA); Jens-Peter Volkmer (Menlo Park, CA); Irving L. Weissman (Stanford, CA)
Assignees: The Board of Trustees of the Leland Stanford Junior University; Forty Seven, LLC
A61K39/3955A61K31/17A61K45/06A61P35/02C07K16/2803A61K2039/505A61K2039/545C07K2317/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,194,093
App. No.
18/143,978
Granted
Jan 14, 2025
Kind
B2
Abstract

Methods are provided herein for determining and administering optimized dosing of therapeutic anti-CD47 agents, in a schedule that provides safe escalation of dose while achieving a therapeutic level in a clinically effective period of time. The methods can comprise the steps of clearance, escalation, and maintenance. In one embodiment the dosing regimen administers an initial (i) sub-therapeutic dose of an anti-CD47 agent or (ii) a cytoreductive therapy to achieve a safe level of circulating tumor cells for subsequent treatment (clearance); escalating the dose of an anti-CD47 agent until a therapeutic dose is reached (escalation); and maintaining the therapeutic dose for a period of time sufficient to reduce tumor cells in the bone marrow of the patient (maintenance). In an alternative dosing regimen, a patient determined to have a safe level of circulating tumor cells at presentation is treated by the steps of escalation and maintenance without initial clearance.

Claims (6)

1. A method of treating a patient for Myelodysplastic Syndrome (MDS), the method comprising: administering to said patient an effective dose of Hu5F9-G4, in combination with an effective dose of azacitidine.

2. The method of claim 1 , wherein Hu5F9-G4 is administered to said patient in an initial dose of 1 mg/kg/dose.

3. The method of claim 1 , wherein Hu5F9-G4 is administered to said patient in successive doses escalated by 1 to 30 mg/kg/dose.

4. The method of claim 1 , wherein Hu5F9-G4 is administered to said patient in successive doses escalated by 15 mg/kg/dose.

5. The method of claim 1 , wherein a maintenance dose of Hu5F9-G4 is 30 mg/kg.

6. The method of claim 1 , wherein the Hu5F9-G4 dose is escalated semi-weekly to bi-weekly.

Assignments (3)
CHANGE OF NAME Recorded Oct 22, 2024
From: FORTY SEVEN, INC.
To: FORTY SEVEN, LLC
Reel/Frame 069213/0526 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2023
From: MAJETI, RAVINDRA; WEISSMAN, IRVING L.
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 064496/0810 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2023
From: CHAO, MARK P.; LIU, JIE; VOLKMER, JENS-PETER
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY; FORTY SEVEN, INC.
Reel/Frame 064496/0860 →
Continuity (4)
Division 17468265 · Sep 7, 2021
Division 16619387
Provisional Application 62523182 · Jun 21, 2017
Related Publication 20230270852A1 · Aug 31, 2023
References Cited (46)
US 8562997B2 · Jaiswal et al. · 2013 [cited by applicant]
US 8758750B2 · Weissman et al. · 2014 [cited by applicant]
US 9396682B2 · Xia et al. · 2016 [cited by applicant]
US 9399682B2 · Jaiswal et al. · 2016 [cited by applicant]
US 9493575B2 · Jaiswal et al. · 2016 [cited by applicant]
US 9623079B2 · Willingham et al. · 2017 [cited by applicant]
US 9796781B2 · Majeti et al. · 2017 [cited by applicant]
US 10301387B2 · Willingham et al. · 2019 [cited by applicant]
US 11136391B2 · Willingham et al. · 2021 [cited by applicant]
US 11141480B2 · Majeti · 2021 [cited by examiner]
US 11518806B2 · Willingham et al. · 2022 [cited by applicant]
US 11603404B2 · Willingham et al. · 2023 [cited by applicant]
US 20100080769A1 · Grillo-Lopez et al. · 2010 [cited by applicant]
US 20160008429A1 · Willingham et al. · 2016 [cited by applicant]
US 20160094698A1 · Lee et al. · 2016 [cited by applicant]
CN 102639565A · 2012 [cited by applicant]
WO WO2011021014A2 · 2011 [cited by applicant]
WO WO2014123580A1 · 2014 [cited by applicant]
WO WO2014149477A1 · 2014 [cited by applicant]
WO WO2015041987A1 · 2015 [cited by applicant]
WO WO2016094698A1 · 2016 [cited by applicant]
WO WO2017053423A1 · 2017 [cited by applicant]
Boasman, K. et al., Role of Pro-Phagocytic Calreticulin and Anti-Phagocytic CD47 in MDS and MPN Models Treated With Azacytidine or Ruxolitinib, Euro. Hema. Assoc., Abstract, 2 pages (2017). <https://library.ehaweb.org/e… [cited by applicant]
Fischer, K. et al., Venetoclax and obinutuzumab in chronic lymphocytic leukemia, Blood, 129(19):2702-2705 (2017). [cited by applicant]
Li, B, Research progress of cytarabine combined with interferon in the treatment of leukemia, Guangdong Chemical Industry, 42:109-131 (2015). [cited by applicant]
Métayer, L. E. et al., Anti-CD47 antibodies induce phagocytosis of live, malignant B cells by macrophages via the Fc domain, resulting in cell death by phagoptosis, Oncotarget, 8(37):60892-60903 (2017). [cited by applicant]
Sallman, D et al., The First-In-Class Anti-CD47 Antibody HU5F9-G4 Is Active And Well Tolerated Alone Or In Combination With Azacitidine In AML And MDS Patients: Initial Phase 1B Results, 24th Congress Euro. Hema. Assoc.… [cited by applicant]
Triozzi, P. L. et al., Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice, Cancer Immunol Immunother, 61:1441-1450 (2012). [cited by applicant]
Zhang, M. et al., Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polartized Macrophages In Vivo, PLOS One, 11(4):1-21 (2016). [cited by applicant]
Clinical Trials: NCT04435691, Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia, 19 pages, First Submitted Jun. 15, 2020, <https://classic.clinicaltrials.gov/ct2/show/NCT04435691>. [cited by applicant]
Clinical Trials: NCT04778397, Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myel… [cited by applicant]
Clinical Trials: NCT05079230, Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia, 15 pages, First Submitted Oct. 4, 2021, <https://clinicaltrial… [cited by applicant]
Font, P., Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia, Adv Ther, vol. 28, Abstract (2011). [cited by applicant]
Liu, J. et al., Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential, PLoS One, 10(9):1-23 (2015). [cited by applicant]
Misaghian, N. et al., Targeting the leukemic stem cell: the holy grail of leukemia therapy, Leukemia, 25-42 (2008). [cited by applicant]
Sutherland, M. S. et al., 5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia, MAbs, 2(4):440-8 (2010). [cited by applicant]
Clinical Trials: NCT04313881, Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (Mds) (Enhance), 15 pages, Study Start: Jan. 9, 2020, <https://classic.clinical… [cited by applicant]
Daver, N. G. et al., Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase lb Results, Jrnl. Clin. Oncol., 41(3… [cited by applicant]
Gilead, Gilead Statement on the Discontinuation of Magrolimab Study in AML with TP53 Mutations, Press Release (Sep. 26, 2023) <https://www.cancertherapyadvisor.com/home/cancer-topics/hematologic-cancers/hematologic-canc… [cited by applicant]
Gilead, Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS, Press Release, 4 pages (Jul. 21, 2023) <https://www.gilead.com/news-and-press/press-room/press-releases/2023/7/gilea… [cited by applicant]
Sallman, D. A. et al., Magrolimab in Combination With Azacitidine in Patients With Higher- Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study, Jrnl. Clin. Oncol., 1-14 (2023). [cited by applicant]
Clinical Trials: NCT04313881, Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (Mds) (Enhance), 15 pages, Study Start Sep. 9, 2020 <https://www.clinicaltrials… [cited by applicant]
Gilead, Enhance Magrolimab Trial Summary, 4 pages posted Feb. 26, 2024. [cited by applicant]
Gilead, Statement on Discontinuation of Phase 3 ENHANCE-3 Study in AML, 4 pages, Posted Feb. 27, 2024, <https://www.gilead.com/news-and-press/company-statements/gilead-statement-on-discontinuation-of-phase-3-enhance-3-s… [cited by applicant]
Qu, T. et al., Ligufalimab, a novel anti-CD47 antibody with No. hemagglutination demonstrates both monotherapy and combo antitumor activity, J. Immunother. Cancer, 10:1-12 (2022). [cited by applicant]
Sikic, B. I. et al., First-in-Human, First-in-Class Phase | Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers, Jrnl. Clin. Onco., 37(12): 946-953 (2019). [cited by applicant]